High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
PHASE2RecruitingINTERVENTIONAL
Enrollment
40
Participants
Timeline
Start Date
May 1, 2022
Primary Completion Date
December 31, 2024
Study Completion Date
March 31, 2025
Conditions
Non-Small Cell Lung Cancer
Interventions
DRUG
Furmonertinib
furmonertinib 160 mg orally QD
Trial Locations (1)
Unknown
RECRUITING
Hunan Cancer hospital, Changsha
All Listed Sponsors
lead
Hunan Province Tumor Hospital
OTHER
NCT05379803 - High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases | Biotech Hunter | Biotech Hunter